Physician profile
Michael G Mayeda
NPI 1972597250
$5,840.32
in general payments reported to CMS, 2019-2025
12 companies · $745 in 2025
The $745 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $422 · 2021: $995 · 2022: $1,390 · 2023: $951 · 2024: $538 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Entertainment: $22.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.95 |
| Entertainment | $22.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,392.79 | 2022-2025 | Infuse, Infuse Multifocal, Btod |
| Coopervision INC. | $2,196.94 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $856.39 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $178.27 | 2019-2025 | Acuvue |
| Optos, INC. | $43.35 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $41.15 | 2021 | |
| Abb Con-Cise Optical Group LLC | $27.12 | 2023 | Spectacle Lenses, Contact Lens |
| Sight Sciences, INC. | $23.51 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.50 | 2025 | |
| Alcon Vision LLC | $21.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.91 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mayeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.